Howard N Bockbrader

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi Clinical pharmacokinetics of pregabalin in healthy volunteers
    Howard N Bockbrader
    Pfizer Global Research and Development, 50 Pequot Ave, New London, CT 06320, USA
    J Clin Pharmacol 50:941-50. 2010
  2. ncbi A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin
    Howard N Bockbrader
    Pfizer Global Research and Development, Ann Arbor, Michigan 48105, USA
    Clin Pharmacokinet 49:661-9. 2010
  3. ncbi Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures
    Howard N Bockbrader
    Neurosciences, Clinical Pharmacology, Pfizer Global Research and Development, New London, Connecticut 06320, USA
    Epilepsia 52:248-57. 2011
  4. ncbi Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine
    Howard N Bockbrader
    Neurosciences, Clinical Pharmacology, Pfizer Global Research and Development, New London, Connecticut 06320, USA
    Epilepsia 52:405-9. 2011
  5. ncbi Pharmacokinetics of pregabalin in subjects with various degrees of renal function
    Edward J Randinitis
    Clinical Sciences Department, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    J Clin Pharmacol 43:277-83. 2003
  6. ncbi Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy
    Martin J Brodie
    Pfizer, Global Research and Development, Ann Arbor, Michigan 48105, USA
    Epilepsia 46:1407-13. 2005

Collaborators

Detail Information

Publications6

  1. ncbi Clinical pharmacokinetics of pregabalin in healthy volunteers
    Howard N Bockbrader
    Pfizer Global Research and Development, 50 Pequot Ave, New London, CT 06320, USA
    J Clin Pharmacol 50:941-50. 2010
    ..Pregabalin demonstrates desirable, predictable pharmacokinetic properties that suggest ease of use. Because pregabalin is eliminated renally, renal function affects its pharmacokinetics...
  2. ncbi A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin
    Howard N Bockbrader
    Pfizer Global Research and Development, Ann Arbor, Michigan 48105, USA
    Clin Pharmacokinet 49:661-9. 2010
    ..In conclusion, pregabalin appears to have some distinct pharmacokinetic advantages over gabapentin that may translate into an improved pharmacodynamic effect...
  3. ncbi Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures
    Howard N Bockbrader
    Neurosciences, Clinical Pharmacology, Pfizer Global Research and Development, New London, Connecticut 06320, USA
    Epilepsia 52:248-57. 2011
    ..The present study investigated the population pharmacokinetics of pregabalin following single and multiple doses in healthy volunteers and patient populations...
  4. ncbi Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine
    Howard N Bockbrader
    Neurosciences, Clinical Pharmacology, Pfizer Global Research and Development, New London, Connecticut 06320, USA
    Epilepsia 52:405-9. 2011
    ..A further clarification study is necessary for tiagabine. In conclusion, it appears that pregabalin can be coadministered with other antiepileptic drugs without concern for significantly altering their pharmacokinetic profiles...
  5. ncbi Pharmacokinetics of pregabalin in subjects with various degrees of renal function
    Edward J Randinitis
    Clinical Sciences Department, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    J Clin Pharmacol 43:277-83. 2003
    ..Supplemental pregabalin doses may be required for patients on chronic hemodialysis treatment after each hemodialysis treatment to maintain steady-state plasma pregabalin concentrations within desired ranges...
  6. ncbi Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy
    Martin J Brodie
    Pfizer, Global Research and Development, Ann Arbor, Michigan 48105, USA
    Epilepsia 46:1407-13. 2005
    ..The PGB-AED combinations were generally well tolerated. PGB may be added to VPA, LTG, PHT, or CBZ therapy without concern for pharmacokinetic drug-drug interactions...